Cargando…

Going -omics to identify novel therapeutic targets for cardiovascular disease

Detalles Bibliográficos
Autores principales:	Harber, Karl J., Verberk, Sanne G.S., Van den Bossche, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443677/ https://www.ncbi.nlm.nih.gov/pubmed/30879921 http://dx.doi.org/10.1016/j.ebiom.2019.03.005

Ejemplares similares

Myeloid-Specific Acly Deletion Alters Macrophage Phenotype In Vitro and In Vivo without Affecting Tumor Growth
por: de Goede, Kyra E., et al.
Publicado: (2021)

Succinate Is an Inflammation-Induced Immunoregulatory Metabolite in Macrophages
por: Harber, Karl J., et al.
Publicado: (2020)

An integrated toolbox to profile macrophage immunometabolism
por: Verberk, Sanne G.S., et al.
Publicado: (2022)

Integrative Omics for Identifying Dysfunctional Pathways in CKD
por: Tin, Adrienne, et al.
Publicado: (2018)

PERK: a novel therapeutic target for neurodegenerative diseases?
por: Ma, Tao, et al.
Publicado: (2014)

Identifying genes that regulate bone remodeling as potential therapeutic targets
por: Krane, Stephen M.
Publicado: (2005)

Should I stay or should I go?
por: Busch, Karl Emanuel, et al.
Publicado: (2012)

The Charcot-Marie-Tooth diseases: how can we identify and develop novel therapeutic targets?
por: Roberts, Rhys C.
Publicado: (2012)

The founding charter of the Omic Biodiversity Observation Network (Omic BON)
por: Meyer, Raïssa, et al.
Publicado: (2023)

Itaconate promotes a wound resolving phenotype in pro-inflammatory macrophages
por: Maassen, Sjors, et al.
Publicado: (2022)

Myeloid ATP Citrate Lyase Regulates Macrophage Inflammatory Responses In Vitro Without Altering Inflammatory Disease Outcomes
por: Verberk, Sanne G. S., et al.
Publicado: (2021)

Going Viral: a Novel Role for Bacteriophage in Colorectal Cancer
por: Handley, Scott A., et al.
Publicado: (2019)

Calnexin revealed as an ether-a-go-go chaperone by getting mutant worms up and going
por: Pierce, Jonathan T.
Publicado: (2018)

Modulating microRNAs as Novel Therapeutic Targets in Cardiac Fibrosis
por: Chen, Zhongxiu, et al.
Publicado: (2017)

Commentary: Go with the flow
por: Burfeind, William R.
Publicado: (2021)

Forward We Go!
por: Nezhat, Farr R., et al.
Publicado: (2023)

Hox go omics: insights from Drosophila into Hox gene targets
por: Pavlopoulos, Anastasios, et al.
Publicado: (2007)

Biomarkers in cancer: is ‘omices’ the way to go
por: Buhmeida, Abdelbaset, et al.
Publicado: (2011)

Commentary: Extrapleural pneumonectomy during myasthenic crisis: The urge to go big or go home
por: Abbas, Abbas E.
Publicado: (2020)

Integrative Omics Analysis of Rheumatoid Arthritis Identifies Non-Obvious Therapeutic Targets
por: Whitaker, John W., et al.
Publicado: (2015)

Multi-omics approach to identifying isoform variants as therapeutic targets in cancer patients
por: Shaw, Timothy I., et al.
Publicado: (2022)

The dawn has come for new therapeutics to treat atherosclerosis: Targeting neuroimmune cardiovascular interfaces in artery brain circuits
por: Mohanta, Sarajo Kumar, et al.
Publicado: (2022)

Axonal Reconstructions Going Live
por: Canty, Alison J., et al.
Publicado: (2011)

Where is biological therapy going?
por: Schulze-Koops, Hendrik, et al.
Publicado: (2000)

No-Go Zones for Mariner Transposition
por: Akerley, Brian J.
Publicado: (2016)

Commentary: When to go “all in”
por: Greenberg, Jason W., et al.
Publicado: (2021)

KRAS inhibitors: going noncovalent
por: Drosten, Matthias, et al.
Publicado: (2022)

Therapeutic potential of tricarboxylic acid cycle metabolite itaconate in cardiovascular diseases
por: Yang, Chongzhe, et al.
Publicado: (2020)

MHC Genomics and Disease: Looking Back to Go Forward
por: Dawkins, Roger L., et al.
Publicado: (2019)

Hopamine as Personalized Medicine for Persons with Parkinson’s Disease
por: Noordegraaf, Marina A., et al.
Publicado: (2023)

NuGO contributions to GenePattern
por: De Groot, P. J., et al.
Publicado: (2008)

Workforce planning—going beyond the count
por: Sandy, Lewis G.
Publicado: (2017)

Commentary: When the going gets… stuck
por: Amabile, Andrea, et al.
Publicado: (2021)

Commentary: Atrial fibrillation? Go hybrid
por: Moscarelli, Marco, et al.
Publicado: (2021)

Novel Strategies to Combat CMV-Related Cardiovascular Disease
por: Vasilieva, Elena, et al.
Publicado: (2020)

Plasma-type gelsolin in subarachnoid hemorrhage: novel biomarker today, therapeutic target tomorrow?
por: Chou, Sherry Hsiang-Yi, et al.
Publicado: (2014)

Commentary: Care for retinopathy of prematurity in the COVID-19 era: When the going gets tough, the tough get going
por: Sen, Parveen, et al.
Publicado: (2022)

Going Beyond Conventional Mammographic Density to Discover Novel Mammogram-Based Predictors of Breast Cancer Risk
por: Hopper, John L, et al.
Publicado: (2020)

Where Do Omics and Markers Go Next?
por: Sharp, Frank R.
Publicado: (2010)

Correction: Integrative Omics Analysis of Rheumatoid Arthritis Identifies Non-Obvious Therapeutic Targets
por: Whitaker, John W., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4al19d4oa0ap1v0c5m9mb27m42